Form 4: Aprea Therapeutics Director Richard Peters Boosts Stake with Equity Grants

Aprea Therapeutics Director Richard Peters was granted 1,045 restricted stock units and 4,185 stock options on June 5, 2025, increasing his beneficial ownership in the company.

Summary

• Richard Peters, a Director of Aprea Therapeutics, Inc. (APRE), reported changes in his beneficial ownership through a Form 4 filing.
• On June 5, 2025, Mr. Peters acquired 1,045 shares of Common Stock in the form of restricted stock units (RSUs) at a grant price of $0.00 per share.
• These RSUs are scheduled to vest and settle in common stock on June 5, 2026, contingent on his continued service on the board of directors.
• Additionally, on June 5, 2025, Mr. Peters acquired 4,185 stock options with an exercise price of $1.81 per share.
• These stock options vest in full on June 5, 2026, also subject to his continued service on the board, and have an expiration date of June 5, 2035.
• Following these transactions, Mr. Peters directly beneficially owns 3,119 shares of Common Stock and 4,185 stock options.

Sentiment

Score: 7

Explanation: The acquisition of additional equity by a director, through both restricted stock units and stock options, generally signals confidence in the company's future prospects and aligns management incentives with shareholder value creation.

Positives

• Director Richard Peters increased his beneficial ownership in Aprea Therapeutics through equity grants, which can signal confidence in the company's future prospects.
• The grant of restricted stock units and stock options aligns the director's interests with those of shareholders, as vesting is tied to continued service and potential stock price appreciation.

Risks

• The vesting of both the 1,045 restricted stock units and 4,185 stock options is contingent upon Richard Peters' continued service on the Issuer's board of directors through the applicable vesting date of June 5, 2026.

Future Outlook

The restricted stock units and stock options granted to Director Richard Peters are set to vest on June 5, 2026, subject to his continued service on the board, aligning his future compensation with the company's performance.

Industry Context

This Form 4 filing is a routine disclosure of insider equity transactions, common across all publicly traded companies, particularly in the biotechnology sector where equity-based compensation is a standard practice for attracting and retaining talent, including board members.

Related Party Transactions

• The grant of restricted stock units and stock options to Richard Peters, a director, constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially encouraging decisions that enhance long-term shareholder value.
• Employees: While not directly impacting general employees, such compensation structures for directors can set a precedent for executive and key employee incentive programs.

Next Steps

• Vesting of 1,045 restricted stock units on June 5, 2026, contingent on continued board service.
• Vesting of 4,185 stock options on June 5, 2026, contingent on continued board service.
• Expiration of 4,185 stock options on June 5, 2035.

Key Dates

Recommendation

Keywords

Aprea Therapeutics, APRE, Form 4, insider transaction, beneficial ownership, restricted stock units, stock options, director compensation, equity grant